Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Julphar
Dow
AstraZeneca
Moodys
Cipla
Cerilliant
Baxter
UBS
Farmers Insurance

Generated: August 23, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Methods for concomitant administration of colchicine and a second active agent
Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
Inventor(s): Davis; Matthew W. (Erwinna, PA)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:13/092,459
Patent Claims: 1. A method of treating a patient in need of treatment for gout or familial Mediterranean fever with colchicine, comprising orally administering an adjusted daily dosage amount of colchicine to the patient who is receiving concomitant administration of a recommended daily dosage amount of ritonavir, wherein the adjusted daily dosage amount of colchicine is 25% to 50% of a daily dosage amount of colchicine suitable for the patient if the patient were not receiving concomitant ritonavir.

2. The method of claim 1, wherein treating with colchicine is for the prophylaxis of gout flares, and wherein the daily dosage amount of colchicine suitable for the patient if the patient were not receiving concomitant ritonavir is 0.6 mg twice daily or 0.6 mg once daily.

3. The method of claim 2 wherein the adjusted daily dosage amount of colchicine is 0.3 mg once daily.

4. The method of claim 2, wherein the adjusted daily dosage amount of colchicine is 0.3 mg once every other day.

5. The method of claim 1, wherein treating with colchicine is for the treatment of gout flares, and wherein the daily dosage amount of colchicine suitable for the patient if the patient were not receiving concomitant ritonavir is 1.2 mg at the first sign of flare, followed by 0.6 mg one hour later, dose to be repeated no earlier than 3 days.

6. The method of claim 5, wherein the adjusted daily dosage amount is 0.6 mg at the first sign of a flare, followed by 0.3 mg one hour later, dose to be repeated no earlier than 3 days.

7. The method of claim 1, wherein treating with colchicine is for treatment of familial Mediterranean fever, and wherein the adjusted daily dosage amount of colchicine is a maximum colchicine dosage amount of 0.3 mg of colchicine twice daily, which is a reduction from the intended daily dosage amount of colchicine in the absence of concomitant ritonavir wherein the intended daily dosage amount is a maximum daily dosage amount as follows: TABLE-US-00021 Daily dosage amount Age Usual Maximum Adults and children > 12 years 1.2 mg 2.4 mg Children > 6 to 12 years 0.9 mg 1.8 mg Children 4 to 6 years 0.3 mg .sup. 1.8 mg.

8. The method of claim 1, wherein the recommended daily dosage amount of ritonavir is 200 mg to 1200 mg per day.

9. The method of claim 1, wherein the recommended daily dosage amount of ritonavir is 200 mg or 1200 mg per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
QuintilesIMS
Queensland Health
Dow
Fuji
Colorcon
Johnson and Johnson
Julphar
Accenture
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot